News Archive

October 2018

• Key Release Oct 18, 2018

  Novartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittliche Therapieplattformen voran, um das zukünftige Wachstum zu beschleunigen

  Der Nettoumsatz steigt um 6% (kWk[1], +3% USD), vor allem dank folgender Beiträge: Cosentyx erzielt mit starken Volumenzuwächsen in allen Indikationen einen Umsatz von USD 750 Millionen (+37% kWk…
• Press Release Oct 16, 2018

  Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis

  Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] …
• Press Release Oct 11, 2018

  Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

  Global resolution secures patient access to Sandoz biosimilar Hyrimoz® (adalimumab)[1] for the reference medicine Humira®** Resolution paves way for 2018 launch in key European markets and…
• Press Release Oct 10, 2018

  Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis

  Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (…
• 
  Story Oct 10, 2018 From Our Labs

  Women in Science: Marjorie Eiref

  Marjorie Eiref, Head of Operations for Neuroscience Research at Novartis, describes how her family medical history has impacted her career.

• Press Release Oct 10, 2018

  Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden

  33 abstracts from the leading MS portfolio include data for Gilenya® (fingolimod), and investigational drugs siponimod (BAF312) and ofatumumab (OMB157) New research will be presented on…
• Press Release Oct 09, 2018

  Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study

  Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or…
• 
  Story Oct 08, 2018 Discovery

  Digital health ecosystem gets a boost with the Novartis Biome

• Press Release Oct 08, 2018

  Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients

  There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of…
• Press Release Oct 04, 2018

  Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges

  Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek…
• Press Release Oct 03, 2018

  Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals

  Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria  Agreement is part of Novartis strategy to…
• 
  Story Oct 01, 2018 Discovery

  Researchers boost understanding of T-cell therapy in blood cancer

  Novartis investigators find genetic explanations for why some young patients relapse.